Denali Therapeutics (DNLI): Assessing Valuation After $200 Million Secondary Offering and FDA Voucher Discussions [Yahoo! Finance]
Is Denali Therapeutics (DNLI) the Most Promising Mid-Cap Healthcare Stock Under $50? [Yahoo! Finance]
How Investors May Respond To Denali Therapeutics (DNLI) $200 Million Equity Raise And FDA Voucher Talks [Yahoo! Finance]
Denali Therapeutics (NASDAQ:DNLI) had its price target lowered by analysts at Wedbush from $31.00 to $30.00. They now have an "outperform" rating on the stock.
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]